Here, we show that BCG hydrogel increased TCR diversity within tumors, which has been previously correlated with beneficial response to immune checkpoint blockade (ICB) therapy.50 In addition, the frequency of tumor-reactive CD8+ T cells was elevated in BCG hydrogel-treated tumors. This evidence concerns the gene CD8A and neoplasm.